AbbVie to Acquire Apogee Therapeutics in $10.9 Billion All-Cash Deal

AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal valued at approximately $10.9 billion. The acquisition aims to bolster AbbVie's pipeline in respiratory diseases. The deal is expected to close in the first half of 2026.

Deal Details

• Total Value: Approximately $10.9 billion.
• Payment Method: All cash.
• Target: Apogee Therapeutics (APGE).
• Premium: Not yet disclosed.
• Expected Closing: First half of 2026.

Rationale

AbbVie seeks to expand its presence in the respiratory disease market, as Apogee Therapeutics has a promising drug candidate for asthma and chronic obstructive pulmonary disease (COPD). The acquisition also aligns with AbbVie's strategy to diversify its revenue sources away from Humira, which faces increasing competition.

Regulatory Challenges

The deal is subject to regulatory approvals, including from the U.S. Federal Trade Commission (FTC). AbbVie has not indicated any expected regulatory hurdles.

Impact on Stocks

No immediate reaction from AbbVie's stock (ABBV) has been reported. Investors are expected to monitor the deal's progress and its impact on the company's cash flows. Apogee Therapeutics' stock (APGE) is likely to rise toward the acquisition price.